-
Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
– Recommendation is Based on Week 26 Data from the CAPELLA Trial Showing Twice-Yearly Lenacapavir Achieved High Rates of Virologic Suppression in Heavily Treatment-Experienced People with HIV – ...
-
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
– All Clinical Studies Evaluating Injectable Lenacapavir to Resume – – Decision Based on Review of Vial Compatibility Data – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, ...
-
– Lenacapavir Maintained High Rates of Virologic Suppression Among Heavily Treatment-Experienced People with Multi-Drug Resistant HIV – – Late-Breaking Preclinical Data Support Further Study of Lenacapavir ...
-
– CRL Cites Issues Related to Compatibility of Vials and Lenacapavir Solution – – No New Clinical Studies Requested in the CRL – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead ...
-
– One-Year Data From the CAPELLA and CALIBRATE Trials Show Lenacapavir Leads to High Rates of Virologic Suppression in Heavily Treatment-Experienced People Living with Multi-Drug Resistant HIV ...
-
– Week 26 Data From the CAPELLA Trial Show Lenacapavir Leads to High Rates of Virologic Suppression in Heavily Treatment-Experienced People Living With Multi-Drug Resistant HIV – FOSTER CITY, Calif.--(BUSINESS ...
-
– European Commission Grants Marketing Authorization for Sunlenca, Helping to Address a Critical Unmet Clinical Need for People with Multi-Drug-Resistant HIV Who Have Very Limited Treatment Choices ...
-
-- Pause Due to Concerns About Compatibility of the Vial Type with the Drug Solution -- FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the ...
-
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of the ...
-
–NDA Resubmission Addresses Issues Related to Vial Compatibility – – If Approved, Lenacapavir Would be the First and the Only HIV-1 Treatment Option Administered Twice-Yearly – FOSTER CITY, Calif.--(BUSINESS ...